Post The Emergence of Philanthropy to Fund High-Risk, High-Reward Cancer Research A Conversation With Jeffrey Bluestone, PhD
Post Friends and Parker Institute for Cancer Immunotherapy Co-Host Summit: Optimizing the Use of Immunotherapy
Post Parker Institute for Cancer Immunotherapy Announces Appointment of Mark Veich as Chief Organizational Advancement Officer
Post Immunai and the Parker Institute Collaborate to Build One of the Largest Single-Cell Datasets in Cancer